277 related articles for article (PubMed ID: 32796360)
41. Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels.
Kang SH; Kim DY; Jeon SM; Ahn SH; Park JY; Kim SU; Kim JK; Lee KS; Chon CY; Han KH
Eur J Gastroenterol Hepatol; 2012 Jul; 24(7):849-56. PubMed ID: 22495400
[TBL] [Abstract][Full Text] [Related]
42. Lens culinaris agglutinin-reactive alpha-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis: a histopathological study of surgically resected hepatocellular carcinoma.
Miyaaki H; Nakashima O; Kurogi M; Eguchi K; Kojiro M
J Gastroenterol; 2007 Dec; 42(12):962-8. PubMed ID: 18085353
[TBL] [Abstract][Full Text] [Related]
43. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group.
Ishii M; Gama H; Chida N; Ueno Y; Shinzawa H; Takagi T; Toyota T; Takahashi T; Kasukawa R
Am J Gastroenterol; 2000 Apr; 95(4):1036-40. PubMed ID: 10763956
[TBL] [Abstract][Full Text] [Related]
44. Usefulness of AFP, PIVKA-II, and Their Combination in Diagnosing Hepatocellular Carcinoma Based on Upconversion Luminescence Immunochromatography.
Zhang SG; Huang Y
Lab Med; 2022 Sep; 53(5):488-494. PubMed ID: 35551399
[TBL] [Abstract][Full Text] [Related]
45. Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis.
Su TH; Peng CY; Chang SH; Tseng TC; Liu CJ; Chen CL; Liu CH; Yang HC; Chen PJ; Kao JH
J Formos Med Assoc; 2022 Mar; 121(3):703-711. PubMed ID: 34452785
[TBL] [Abstract][Full Text] [Related]
46. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion.
Poté N; Cauchy F; Albuquerque M; Voitot H; Belghiti J; Castera L; Puy H; Bedossa P; Paradis V
J Hepatol; 2015 Apr; 62(4):848-54. PubMed ID: 25450201
[TBL] [Abstract][Full Text] [Related]
47. Usefulness of PIVKA-II After Living-donor Liver Transplantation for Hepatocellular Carcinoma.
Park MS; Lee KW; Kim H; Choi YR; Hong G; Yi NJ; Suh KS
Transplant Proc; 2017 Jun; 49(5):1109-1113. PubMed ID: 28583537
[TBL] [Abstract][Full Text] [Related]
48. Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis.
Caviglia GP; Ribaldone DG; Abate ML; Ciancio A; Pellicano R; Smedile A; Saracco GM
Scand J Gastroenterol; 2018 Jun; 53(6):734-740. PubMed ID: 29667463
[TBL] [Abstract][Full Text] [Related]
49. Clinical value of serum AFP and PIVKA-II for diagnosis, treatment and prognosis of hepatocellular carcinoma.
Tian S; Chen Y; Zhang Y; Xu X
J Clin Lab Anal; 2023 Jan; 37(1):e24823. PubMed ID: 36579611
[TBL] [Abstract][Full Text] [Related]
50. Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region.
Kim DY; Toan BN; Tan CK; Hasan I; Setiawan L; Yu ML; Izumi N; Huyen NN; Chow PK; Mohamed R; Chan SL; Tanwandee T; Lee TY; Hai TTN; Yang T; Lee WC; Chan HLY
Clin Mol Hepatol; 2023 Apr; 29(2):277-292. PubMed ID: 36710606
[TBL] [Abstract][Full Text] [Related]
51. Biological response under treatment and prognostic value of protein induced by vitamin K absence or antagonist-II in a French cohort of patients with hepatocellular carcinoma.
Payancé A; Dioguardi Burgio M; Peoc'h K; Achahboun M; Albuquerque M; Devictor J; Chor H; Manceau H; Soubrane O; Durand F; Castera L; Bouattour M; Paradis V
Eur J Gastroenterol Hepatol; 2020 Oct; 32(10):1364-1372. PubMed ID: 31895908
[TBL] [Abstract][Full Text] [Related]
52. Comprehensive evaluation of microRNA as a biomarker for the diagnosis of hepatocellular carcinoma.
Malik J; Klammer M; Rolny V; Chan HL; Piratvisuth T; Tanwandee T; Thongsawat S; Sukeepaisarnjaroen W; Esteban JI; Bes M; Köhler B; Swiatek-de Lange M
World J Gastroenterol; 2022 Aug; 28(29):3917-3933. PubMed ID: 36157551
[TBL] [Abstract][Full Text] [Related]
53. Clinical usefulness of double biomarkers AFP and PIVKA-II for subdividing prognostic groups in locally advanced hepatocellular carcinoma.
Park H; Kim SU; Park JY; Kim DY; Ahn SH; Chon CY; Han KH; Seong J
Liver Int; 2014 Feb; 34(2):313-21. PubMed ID: 23895043
[TBL] [Abstract][Full Text] [Related]
54. Diagnostic Performance of Alpha-Fetoprotein, Protein Induced by Vitamin K Absence, Osteopontin, Dickkopf-1 and Its Combinations for Hepatocellular Carcinoma.
Jang ES; Jeong SH; Kim JW; Choi YS; Leissner P; Brechot C
PLoS One; 2016; 11(3):e0151069. PubMed ID: 26986465
[TBL] [Abstract][Full Text] [Related]
55. The diagnostic performance of AFP and PIVKA-II models for non-B non-C hepatocellular carcinoma.
Tran VT; Phan TT; Nguyen TB; Le TT; Tran TT; Nguyen AT; Nguyen HT; Nguyen NB; Ho TT; Pho SP; Nguyen TT; Nguyen HT; Mai HT; Pham BT; Nguyen KD; Le BT; Nguyen TT; Nguyen ST
BMC Res Notes; 2023 Nov; 16(1):317. PubMed ID: 37932802
[TBL] [Abstract][Full Text] [Related]
56. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.
Kim HS; Park JW; Jang JS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
J Clin Gastroenterol; 2009; 43(5):482-8. PubMed ID: 19197197
[TBL] [Abstract][Full Text] [Related]
57. Assessment of KL-6 as a tumor marker in patients with hepatocellular carcinoma.
Gad A; Tanaka E; Matsumoto A; Wahab MA; Serwah Ael-H; Attia F; Ali K; Hassouba H; el-Deeb Ael-R; Ichijyo T; Umemura T; Muto H; Yoshizawa K; Kiyosawa K
World J Gastroenterol; 2005 Nov; 11(42):6607-12. PubMed ID: 16425352
[TBL] [Abstract][Full Text] [Related]
58. Diagnostic performance of tumor markers AFP and PIVKA-II in Chinese hepatocellular carcinoma patients.
Huang S; Jiang F; Wang Y; Yu Y; Ren S; Wang X; Yin P; Lou J
Tumour Biol; 2017 Jun; 39(6):1010428317705763. PubMed ID: 28621228
[TBL] [Abstract][Full Text] [Related]
59. Efficacy of PIVKA-II in prediction and early detection of hepatocellular carcinoma: a nested case-control study in Chinese patients.
Yu R; Xiang X; Tan Z; Zhou Y; Wang H; Deng G
Sci Rep; 2016 Oct; 6():35050. PubMed ID: 27731353
[TBL] [Abstract][Full Text] [Related]
60. Clinical features of hepatitis C virus-related hepatocellular carcinoma and their association with alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II.
Yano Y; Yamashita F; Kuwaki K; Fukumori K; Kato O; Yamamoto H; Ando E; Tanaka M; Sata M
Liver Int; 2006 Sep; 26(7):789-95. PubMed ID: 16911460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
